Reversing oral anticoagulants with a focus on Andexanet Alfa
20:59
Anticoagulant Reversal
1:00:57
Update on Andexanet Alfa for Reversal of FXa Inhibitors: Annexa-I Trial Webinar
50:55
Choosing Wisely to Achieve Control With BTK Inhibitors in CLL
56:16
VTE and Movement
27:51
Direct-Acting Oral Anticoagulants (DOACs) | MOA , Indications, Adverse Reactions, Contraindications
1:14:16
DOACs in cancer associated thrombosis: Sub-group challenges and considerations
8:09
ESC: Apixaban May Be the Real Thing
58:43